7-(3-Phenylpropoxy)Coumarin

7-(3-Phenylpropoxy)Coumarin

SCHEMBL5617866

O=c1ccc2ccc(OCCCc3ccccc3)cc2o1

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 9/20 0.72
CA12 O43570 8/20 0.72
CA9 Q16790 8/20 0.72
CA1 P00915 7/20 0.72
MAOA P21397 7/20 0.72
CA7 P43166 5/20 0.72
CA14 Q9ULX7 5/20 0.72
CA2 P00918 4/20 0.72
CA6 P23280 4/20 0.72
CA4 P22748 4/20 0.72
CA3 P07451 3/20 0.72
MEN1 O00255 1/20 0.72
NPC1 O15118 1/20 0.72
MTNR1A P48039 1/20 0.72
KMT2A Q03164 1/20 0.72
CA5B Q9Y2D0 4/20 0.68
CA5A P35218 3/20 0.63
KDM4E B2RXH2 2/20 0.60
LMNA P02545 1/20 0.60
POLB P06746 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7431108 0.95 CA12 (0.69) MAOBCA12CA9CA1MAOA
7-Benzyloxycoumarin SCHEMBL29365449 0.84 MAOB (1.00) MAOBCA12CA9CA1MAOA
7-Benzyloxycoumarin SCHEMBL3901170 0.84 MAOB (1.00) MAOBCA12CA9CA1MAOA
SCHEMBL24045405 0.84 CA12 (0.82) MAOBCA12CA9CA1MAOA
SCHEMBL12304245 0.83 CA12 (0.81) MAOBCA12CA9CA1MAOA
SCHEMBL31086804 0.81 CA12 (0.77) MAOBCA12CA9CA1MAOA
SCHEMBL9214643 0.81 CA12 (0.77) MAOBCA12CA9CA1MAOA
SCHEMBL31086623 0.81 CA12 (0.77) MAOBCA12CA9CA1MAOA
7-Butoxycoumarin SCHEMBL6686295 0.81 CA12 (1.00) MAOBCA12CA9CA1MAOA
Hydrochloric Acid SCHEMBL8179167 0.80 DRD4 (0.70) MAOBCA12CA9CA1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070078172-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2007-04-05 US claimed
US-20070078172-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2007-04-05 US disclosed
WO-2006138475-A2 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2006-12-28 WO disclosed
EP-0363793-B1 ARYL ALKOXY COUMARINS, PROCESS FOR THEIR PRODUCTION AND THERAPEUTIC AGENTS CONTAINING THEM BASF Aktiengesellschaft (DE) 1993-04-21 EP disclosed
US-5100914-A Monoamine Oxidase Inhibitors, Central Nervous System Disorders BASF AKTIENGESELLSCHAFT (DE) 1992-03-31 US disclosed
EP-0363793-A1 Aryl alkoxy coumarins, process for their production and therapeutic agents containing them BASF Aktiengesellschaft (DE) 1990-04-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078172-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY MAOB, MAOA, GPR119 MAOB 1/4885CA12 4798/4885CA9 3695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.